Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 280 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Testosterone Therapy Clear all

Conditions: Transgenderism
Interventions: Transdermal patch, Pro-thrombotic markers, Metabolic markers, Hormone Profile, Daily Sublingual Tablet, BID Sublingual Tablet, Spironolactone; Drug · Diagnostic Test
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 30 Years · Male only
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Hypogonadism, Male, End Stage Renal Disease (ESRD), Kidney Transplant
Interventions: Testosterone Replacement Therapy; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Prostate Cancer
Interventions: DFMO, testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue, Enzalutamide; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cancer Survivor, Sexual Dysfunction, Sexuality and Reproductive Issues, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: therapeutic testosterone, placebo; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 16
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Urbana, Illinois + 13 more

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: Testosterone cypionate (Tc), ADT with Luteinizing hormone-releasing hormone (LHRH) analog, PSMA-617; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Male Hypogonadism
Interventions: Testosterone Cypionate 75 mg, Testosterone cypionate 50 mg, Testosterone cypionate 100 mg; Drug
Lead sponsor: Amneal Pharmaceuticals, LLC; Industry
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 10
States / cities: Santa Monica, California • DeLand, Florida • Miami Lakes, Florida + 7 more

Conditions: Spinal Cord Injuries, Endothelial Dysfunction, Testosterone Deficiency
Interventions: Intra-arterial Infusion of Vasoactive Agents, Intra-arterial Vitamin C Infusion, Blood Sampling; Diagnostic Test
Lead sponsor: Craig Hospital; Other
Eligibility: 18 Years to 89 Years · Male only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Englewood, Colorado

Conditions: Pelvic Pain, Endometriosis
Interventions: Psychophysical assessment, Psychophysical assessments of experimental pain, Blood, urine and saliva samples, Biopsy and surgery-related data.; Other · Behavioral · Diagnostic Test + 1 more
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 12 Years to 45 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Prostate Cancer
Interventions: therapeutic testosterone; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypoactive Sexual Desire Disorder
Interventions: Testosterone Transdermal System, placebo patch; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 20 Years to 70 Years · Female only
Enrollment: 533 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Healthy Males, Male Contraceptive
Interventions: First Intervention (7 days), First Washout (7 days), Second Intervention (7 days), Third Intervention (7 days), Second wash-out period; Drug · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Spinal Cord Injury, Spinal Cord Injuries, Trauma, Nervous System, Wounds and Injury, Central Nervous System Diseases, Spinal Cord Diseases, Gonadal Disorders, Endocrine System Diseases, Hypogonadism, Genital Diseases, Male, Spinal Cord Trauma, Injuries, Spinal Cord, Walking, Difficulty, Gait Disorders, Neurologic, Locomotion Disorder, Neurologic, Wounds and Injuries, Nervous System Diseases, Testosterone Deficiency, Androgen Deficiency, Hormone Deficiency
Interventions: Testosterone Enanthate, Locomotor Training; Drug · Behavioral
Lead sponsor: North Florida Foundation for Research and Education; Other
Eligibility: 18 Years and older · Male only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Gainesville, Florida • Jacksonville, Florida

Conditions: Primary or Secondary Hypogonadism, Constitutional Delay in Growth and Puberty (CDGP)
Interventions: Testosterone Gel (1%); Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 13 Years to 17 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 19
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 14 more

Conditions: Spinal Cord Injury, Hypogonadism
Interventions: Testosterone Transdermal System (Androderm 5 mg patch); Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 49 Years · Male only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2012
U.S. locations: 2
States / cities: West Orange, New Jersey • The Bronx, New York

Conditions: Kallmann Syndrome, Hypogonadotropic Hypogonadism, GnRH Deficiency
Interventions: gonadotropin releasing hormone (GnRH); Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 16 Years and older
Enrollment: 624 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1989 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypogonadism
Interventions: AndroGel 1.62%; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 45
States / cities: Foley, Alabama • Newport Beach, California • Northridge, California + 40 more

Conditions: Kidney Failure, Kidney Diseases
Interventions: Testim, 1% testosterone gel; Drug
Lead sponsor: Palo Alto Veterans Institute for Research; Other
Eligibility: 45 Years to 80 Years · Male only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 2
States / cities: Palo Alto, California • San Jose, California

Conditions: Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
Interventions: Biopsy of Prostate, Biospecimen Collection, Magnetic Resonance Imaging, Patient Observation, Questionnaire Administration, Therapeutic Testosterone; Procedure · Other · Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Depressive Disorder, Major
Interventions: Testosterone gel, Placebo; Drug
Lead sponsor: Mclean Hospital; Other
Eligibility: 30 Years to 65 Years · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Erectile Dysfunction, Hypogonadism, Male, Endothelial Dysfunction
Interventions: Daily low-dose PDE5 inhibitor therapy, Testosterone therapy as per clinical guidelines.; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older · Male only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Hypogonadism, Malignant Urinary System Neoplasm, Urinary System Disorder, Urinary System Neoplasm
Interventions: Best Practice, Quality-of-Life Assessment, Questionnaire Administration, Testosterone Cypionate; Other · Procedure · Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Hypogonadism, Male
Interventions: Clomiphene; Drug
Lead sponsor: Phoenix VA Health Care System; Federal
Eligibility: 30 Years to 70 Years · Male only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Prostate Cancer
Interventions: Orteronel, Placebo, Prednisone; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,560 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 48
States / cities: Anchorage, Alaska • Tucson, Arizona • Duarte, California + 45 more

Conditions: Hypoactive Sexual Desire Disorder
Interventions: Testosterone Transdermal System, Placebo patch; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 40 Years to 70 Years · Female only
Enrollment: 610 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Denver, Colorado

Search by objective public record fields.

Transgender Estradiol Affirming Therapy

TRT as an Adjunctive ERAS Therapy in ESRD Patients Undergoing Kidney Transplantation

Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

Low-Dose Testosterone in Improving Libido in Postmenopausal Female Cancer Survivors

Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC

Safety and Efficacy of Weekly Testosterone Cypionate Auto-Injector in Men With Hypogonadism

Testosterone Deficiency and Endothelial Dysfunction After Spinal Cord Injury

Endometriosis Pain

Testosterone in Treating Patients With Progressive Prostate Cancer That No Longer Responds to Hormone Therapy

Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido

Oral T7 Oral Testosterone in Man

Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury

Observation Study of T-Gel (1%) in Treatment of Adolescent Boys With Hypogonadism

Testosterone Replacement Therapy in Chronic Spinal Cord Injury

Examination of Idiopathic Hypogonadotropic Hypogonadism (IHH)and Kallmann Syndrome (KS)

A Study of the Effect of Topical Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism

Testosterone Replacement Therapy in Advanced Chronic Kidney Disease

Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance

AndroGel in Men With Major Depression and Incomplete Response to Antidepressant Treatment

EndoPAT Device for Endothelial Dysfunction in ED

Perioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients With Low Testosterone

Clomid in Men With Low Testosterone With and Without Prior Treatment

Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer

Study of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido